{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:12:56Z","timestamp":1791483176319,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,1,11]],"date-time":"2018-01-11T00:00:00Z","timestamp":1515628800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s40264-017-0626-y","type":"journal-article","created":{"date-parts":[[2018,1,11]],"date-time":"2018-01-11T13:13:46Z","timestamp":1515676426000},"page":"523-536","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Signal Detection for Recently Approved Products: Adapting and Evaluating Self-Controlled Case Series Method Using a US Claims and UK Electronic Medical Records Database"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2109-0012","authenticated-orcid":false,"given":"Xiaofeng","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian. J.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongjun.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew.","family":"Bate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,11]]},"reference":[{"issue":"2","key":"626_CR1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/oxfordjournals.aje.a113525","volume":"117","author":"SW Carr Van De","year":"1983","unstructured":"Van De Carr SW, Kennedy DL, Rosa FW, et al. Relationship of oral contraceptive estrogen dose to age. Am J Epidemiol. 1983;117(2):153\u20139.","journal-title":"Am J Epidemiol"},{"issue":"4","key":"626_CR2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/clpt.1985.188","volume":"38","author":"BL Strom","year":"1985","unstructured":"Strom BL, Carson JL, Morse ML, et al. The computerized on-line medicaid pharmaceutical analysis and surveillance system: a new resource for postmarketing drug surveillance. Clin Pharmacol Ther. 1985;38(4):359\u201364.","journal-title":"Clin Pharmacol Ther"},{"issue":"6779","key":"626_CR3","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1136\/bmj.302.6779.766","volume":"302","author":"H Jick","year":"1991","unstructured":"Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ. 1991;302(6779):766\u20138.","journal-title":"BMJ"},{"key":"626_CR4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.0954-6820.1984.tb08728.x","volume":"683","author":"JK Jones","year":"1984","unstructured":"Jones JK, Van de Carr SW, Rosa F, et al. Medicaid drug-event data: an emerging tool for evaluation of drug risk. Acta Med Scand Suppl. 1984;683:127\u201334.","journal-title":"Acta Med Scand Suppl"},{"issue":"6","key":"626_CR5","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427\u201336.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"626_CR6","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/pds","volume":"21","author":"PM Coloma","year":"2012","unstructured":"Coloma PM, Trifir\u00f2 G, Schuemie MJ, et al. Electronic healthcare databases for active drug safety surveillance: is there enough leverage? Pharmacoepidemiol Drug Saf. 2012;21:611\u201321. https:\/\/doi.org\/10.1002\/pds.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"6","key":"626_CR7","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/pds.3258","volume":"21","author":"GN Nor\u00e9n","year":"2012","unstructured":"Nor\u00e9n GN, Hopstadius J, Bate A, et al. Safety surveillance of longitudinal databases: results on real-world data [letter]. Pharmacoepidemiol Drug Saf. 2012;21(6):673\u20135.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"626_CR8","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s40264-015-0341-5","volume":"38","author":"AC Pacurariu","year":"2015","unstructured":"Pacurariu AC, Straus SM, Trifir\u00f2 G, et al. Useful interplay between spontaneous ADR reports and electronic healthcare records in signal detection. Drug Saf. 2015;38(12):1201\u201310.","journal-title":"Drug Saf."},{"issue":"12","key":"626_CR9","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/pds.1836","volume":"18","author":"G Trifir\u00f2","year":"2009","unstructured":"Trifir\u00f2 G, Pariente A, Coloma PM, et al. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Pharmacoepidemiol Drug Saf. 2009;18(12):1176\u201384.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"626_CR10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40264-012-0009-3","volume":"36","author":"X Zhou","year":"2013","unstructured":"Zhou X, Murugesan S, Bhullar H, et al. An evaluation of the THIN database in OMOP common data model for active drug safety surveillance. Drug Saf. 2013;36:119\u201334.","journal-title":"Drug Saf"},{"key":"626_CR11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2307\/2533328","volume":"51","author":"CP Farrington","year":"1995","unstructured":"Farrington CP. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics. 1995;51:228\u201335.","journal-title":"Biometrics"},{"issue":"16","key":"626_CR12","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/eurheartj\/ehu263","volume":"36","author":"R Brauer","year":"2015","unstructured":"Brauer R, Smeeth L, Anaya-Izquierdo K, et al. Antipsychotic drugs and risks of myocardial infarction: a self-controlled case series study. Eur Heart J. 2015;36(16):984\u201392.","journal-title":"Eur Heart J"},{"issue":"9","key":"626_CR13","doi-asserted-by":"crossref","first-page":"e1000154","DOI":"10.1371\/journal.pmed.1000154","volume":"6","author":"IJ Douglas","year":"2009","unstructured":"Douglas IJ, Evans SJ, Pocock S, et al. The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med. 2009;6(9):e1000154.","journal-title":"PLoS Med"},{"key":"626_CR14","doi-asserted-by":"crossref","first-page":"f1936","DOI":"10.1136\/bmj.f1936","volume":"346","author":"IJ Douglas","year":"2013","unstructured":"Douglas IJ, Langham J, Bhaskaran K, et al. Orlistat and the risk of acute liver injury: self-controlled case series study in UK Clinical Practice Research Datalink. BMJ. 2013;346:f1936.","journal-title":"BMJ"},{"issue":"10","key":"626_CR15","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/sim.2302","volume":"25","author":"HJ Whitaker","year":"2006","unstructured":"Whitaker HJ, Farrington CP, Spiessens B, et al. Tutorial in biostatistics: the self-controlled case series method. Stat Med. 2006;25(10):1768\u201397.","journal-title":"Stat Med"},{"issue":"1","key":"626_CR16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/0962280208092342","volume":"18","author":"HJ Whitaker","year":"2009","unstructured":"Whitaker HJ, Hocine MN, Farrington CP, et al. The methodology of self-controlled case series studies. Stat Methods Med Res. 2009;18(1):7\u201326.","journal-title":"Stat Methods Med Res"},{"issue":"3","key":"626_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1517\/14740338.2011.562187","volume":"10","author":"A Grosso","year":"2011","unstructured":"Grosso A, Douglas I, MacAllister R, et al. Use of the self-controlled case series method in drug safety assessment. Expert Opin Drug Saf. 2011;10(3):337\u201340. https:\/\/doi.org\/10.1517\/14740338.2011.562187.","journal-title":"Expert Opin Drug Saf."},{"issue":"4","key":"626_CR18","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/biom.12078","volume":"69","author":"SE Simpson","year":"2013","unstructured":"Simpson SE, Madigan D, Zorych I, et al. Multiple self-controlled case series for large-scale longitudinal observational databases. Biometrics. 2013;69(4):893\u2013902.","journal-title":"Biometrics"},{"issue":"Suppl 1","key":"626_CR19","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1007\/s40264-013-0100-4","volume":"36","author":"MA Suchard","year":"2013","unstructured":"Suchard MA, Zorych I, Simpson SE, et al. Empirical performance of the self-controlled case series design: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S83\u201393.","journal-title":"Drug Saf"},{"issue":"Suppl 1","key":"626_CR20","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1007\/s40264-013-0095-x","volume":"36","author":"GN Noren","year":"2013","unstructured":"Noren GN, Bergvall T, Ryan PB, et al. Empirical performance of the calibrated self-controlled cohort analysis within temporal pattern discovery: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S107\u201321.","journal-title":"Drug Saf"},{"issue":"Suppl 1","key":"626_CR21","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1007\/s40264-013-0097-8","volume":"36","author":"PB Ryan","year":"2013","unstructured":"Ryan PB, Schuemie MJ, Welebob E, et al. Defining a reference set to support methodological research in drug safety. Drug Saf. 2013;36(Suppl 1):S33\u201347.","journal-title":"Drug Saf"},{"issue":"30","key":"626_CR22","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1002\/sim.5620","volume":"31","author":"PB Ryan","year":"2012","unstructured":"Ryan PB, Madigan D, Stang PE, et al. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012;31(30):4401\u201315.","journal-title":"Stat Med"},{"key":"626_CR23","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/pds.1335","volume":"16","author":"JD Lewis","year":"2007","unstructured":"Lewis JD, Schinnar R, Bilker WB, et al. Validation studies of The Health Improvement Network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf. 2007;16:393\u2013401.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"626_CR24","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12876-015-0373-4","volume":"15","author":"NC Lin","year":"2015","unstructured":"Lin NC, Norman H, Regev A, et al. Hepatic outcomes among adults taking duloxetine: a retrospective cohort study in a US health care claims database. BMC Gastroenterol. 2015;15:134.","journal-title":"BMC Gastroenterol."},{"issue":"2","key":"626_CR25","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/archinte.167.2.188","volume":"167","author":"JB Richards","year":"2007","unstructured":"Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med. 2007;167(2):188\u201394.","journal-title":"Arch Intern Med."},{"key":"626_CR26","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00198-011-1778-8","volume":"23","author":"Q Wu","year":"2012","unstructured":"Wu Q, Bencaz AF, Hentz JG, et al. Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case\u2013control studies. Osteoporos Int. 2012;23:365\u201375. https:\/\/doi.org\/10.1007\/s00198-011-1778-8.","journal-title":"Osteoporos Int"},{"key":"626_CR27","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0140-6736(97)09528-7","volume":"351","author":"B Liu","year":"1998","unstructured":"Liu B, Anderson G, Mittmann N, et al. Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet. 1998;351:1303\u20137.","journal-title":"Lancet"},{"issue":"1","key":"626_CR28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/aje\/kwg114","volume":"158","author":"R Hubbard","year":"2003","unstructured":"Hubbard R, Farrington P, Smith C, et al. Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol. 2003;158(1):77\u201384.","journal-title":"Am J Epidemiol"},{"key":"626_CR29","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/pds.3451","volume":"22","author":"W Hua","year":"2013","unstructured":"Hua W, Sun G, Dodd CN, et al. A simulation study to compare three self-controlled case series approaches: correction for violation of assumption and explanation of bias. Pharmacoepidemiol Drug Saf. 2013;22:819\u201325.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"626_CR30","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2165\/00002018-200427100-00004","volume":"27","author":"M Hauben","year":"2004","unstructured":"Hauben M, Reich L. Safety related drug-labelling changes: findings from two data mining algorithms. Drug Saf. 2004;27(10):735\u201344 (published erratum appears in Drug Saf 2006;29(12):1191).","journal-title":"Drug Saf."},{"issue":"6","key":"626_CR31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2165\/00002018-200932060-00007","volume":"32","author":"AM Hochberg","year":"2009","unstructured":"Hochberg AM, Hauben M, Pearson RK, et al. An evaluation of three signal-detection algorithms using a highly inclusive reference event database. Drug Saf. 2009;32(6):509\u201325.","journal-title":"Drug Saf."},{"key":"626_CR32","unstructured":"Foundation for National Institutes of Health, OMOP. Observational analysis methods and methods library. http:\/\/omop.org\/MethodsLibrary. Accessed 6 Nov 2013."},{"key":"626_CR33","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/pds.4065","volume":"25","author":"S Gruber","year":"2016","unstructured":"Gruber S, Chakravarty A, Heckbert SR, et al. Design and analysis choices for safety surveillance evaluations need to be tuned to the specifics of the hypothesized drug\u2013outcome association. Pharmacoepidemiol Drug Saf. 2016;25:973\u201381.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"626_CR34","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/pds.1115","volume":"14","author":"J Lewis","year":"2005","unstructured":"Lewis J, Bilker WB, Weinstein RB, et al. The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol Drug Saf. 2005;14:443\u201351.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"626_CR35","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1365-2125.2008.03263.x","volume":"66","author":"P Traczewski","year":"2008","unstructured":"Traczewski P, Rudnicka L. Adalimumab in dermatology. Br J Clin Pharmacol. 2008;66(5):618\u201325.","journal-title":"Br J Clin Pharmacol."},{"key":"626_CR36","unstructured":"Humira (adalimumab) label. FDA, 2011. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125057s0276lbl.pdf. Accessed 3 Dec 2017."},{"key":"626_CR37","unstructured":"Ryan P. Highlights from the Observational Medical Outcomes Partnership\u2019s (OMOP) annual symposium. Brookings roundtable on active medical product surveillance, 8 Aug 2012. http:\/\/omop.org. Accessed 25 Oct 2016."},{"issue":"3","key":"626_CR38","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1080\/19466315.2013.791638","volume":"5","author":"P Ryan","year":"2013","unstructured":"Ryan P, Schuemie MA, Madigan D. Learning from epidemiology: interpreting observational database studies for the effects of medical products. Stat Biopharm Res. 2013;5(3):170\u20139.","journal-title":"Stat Biopharm Res"},{"key":"626_CR39","doi-asserted-by":"crossref","unstructured":"Falck-Ytter Y, Guyatt GH. Chapter 3: Guidelines: Rating the Quality of Evidence and Grading the Strength of Recommendations. In: Burneo J, Demaerschalk B, Jenkins M (eds), Neurology. New York: Springer; 2012","DOI":"10.1007\/978-0-387-88555-1_3"},{"issue":"337","key":"626_CR40","doi-asserted-by":"crossref","first-page":"a1227","DOI":"10.1136\/bmj.a1227","volume":"28","author":"IJ Douglas","year":"2008","unstructured":"Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self-controlled case series study. BMJ. 2008;28(337):a1227.","journal-title":"BMJ."},{"key":"626_CR41","unstructured":"Humira (adalimumab) label. FDA, 2002. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2002\/adalabb123102LB.htm. Accessed 5 Nov 2017."},{"issue":"7","key":"626_CR42","doi-asserted-by":"crossref","first-page":"737e44","DOI":"10.1001\/jama.2009.146","volume":"301","author":"A Strangfeld","year":"2009","unstructured":"Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF alpha agents. JAMA. 2009;301(7):737e44.","journal-title":"JAMA"},{"issue":"11","key":"626_CR43","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2165\/00002018-200831110-00008","volume":"31","author":"J Hopstadius","year":"2008","unstructured":"Hopstadius J, Noren GN, Bate A, et al. Impact of stratification in adverse drug reaction surveillance. Drug Saf. 2008;31(11):1035\u201348.","journal-title":"Drug Saf"},{"key":"626_CR44","unstructured":"Gagne JJ, Nelson JC, Fireman B. Taxonomy for monitoring methods within a medical product safety surveillance system: year two report of the Mini-Sentinel Taxonomy Project Workgroup. https:\/\/www.sentinelinitiative.org\/sites\/default\/files\/Drugs\/Assessments\/Mini-Sentinel_Methods_Taxonomy-Year-2-Report.pdf. Accessed 5 may 2017."},{"issue":"10","key":"626_CR45","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2165\/00002018-200528100-00002","volume":"28","author":"P Waller","year":"2005","unstructured":"Waller P, Heeley E, Moseley J. Impact analysis of signals detected from spontaneous adverse drug reaction reporting data. Drug Saf. 2005;28(10):843\u201350.","journal-title":"Drug Saf."},{"key":"626_CR46","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/(SICI)1099-1557(199912)8:7<535::AID-PDS456>3.0.CO;2-D","volume":"8","author":"PC Waller","year":"1999","unstructured":"Waller PC, Lee EH. Responding to drug safety issues. Pharmacoepidemiol Drug Saf. 1999;8:535\u2013552","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"Suppl 1","key":"626_CR47","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1002\/(SICI)1099-1557(199904)8:1+<S15::AID-PDS402>3.3.CO;2-2","volume":"8","author":"M Lindquist","year":"1999","unstructured":"Lindquist M, Edwards IR, Bate A, et al. From association to alert\u2014a revised approach to international signal analysis. Pharmacoepidemiol Drug Saf. 1999;8(Suppl 1):S15\u201325.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-017-0626-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0626-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0626-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T12:33:05Z","timestamp":1719750785000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-017-0626-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,11]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["626"],"URL":"https:\/\/doi.org\/10.1007\/s40264-017-0626-y","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,11]]}}}